Literature DB >> 3410332

Mucosal biotransformation rates in the small intestine of children.

M R Ståhlberg1, E Hietanen, M Mäki.   

Abstract

Biotransformation of ingested xenobiotics is known to take place in the gastrointestinal mucosa of laboratory animals and adult humans as well as in the liver. We studied the activities of aryl hydrocarbon hydroxylase, epoxide hydrolase, and glutathione peroxidase in 242 peroral small intestinal biopsy samples of children aged eight months to 18 years: 201 with normal histology, 21 with partial villous atrophy, and 20 with severe villous atrophy. All these enzymes were detectable even in the youngest children. The aryl hydrocarbon hydroxylase activity was age dependent, while the other measured enzyme activities were not related to the age of the patients. The aryl hydrocarbon hydroxylase activity was not related to the mucosal histology, but the epoxide hydrolase and glutathione peroxidase activities were diminished in samples with severe villous atrophy as compared with normal mucosa. This suggests that small intestinal mucosa with villous atrophy may produce oxidated, reactive metabolites, but further metabolism into detoxication products is decreased. This may expose persons with mucosal atrophy to possible harmful effects of environmental xenobiotics entering the body even at low doses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3410332      PMCID: PMC1433902          DOI: 10.1136/gut.29.8.1058

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  32 in total

1.  Concomitant dietary exposure to polychlorinated biphenyls and polybrominated biphenyls: tissue distribution and arylhydrocarbon hydroxylase activity in lactating rats.

Authors:  K M McCormack; P Melrose; D E Rickert; J G Dent; J E Gibson; J B Hook
Journal:  Toxicol Appl Pharmacol       Date:  1979-01       Impact factor: 4.219

Review 2.  Physiological defence against xenobiotics at their portals of entry to the organism.

Authors:  O Hänninen; A Aitio; E Hietanen
Journal:  Med Biol       Date:  1979-10

3.  Dependence of intestinal biotransformation on dietary cholesterol.

Authors:  E Hietanen; M Laitinen
Journal:  Biochem Pharmacol       Date:  1978-04-01       Impact factor: 5.858

4.  Effects of semisynthetic diets on xenobiotic metabolizing enzyme activity and morphology of small intestinal mucosa in humans.

Authors:  H P Hoensch; H J Steinhardt; G Weiss; D Haug; A Maier; H Malchow
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

5.  Coeliac disease and malignancy.

Authors:  C M Swinson; G Slavin; E C Coles; C C Booth
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

6.  Oxidation and subsequent glucuronidation of 3,4-benzopyrene in everted intestinal sacs in control and 3-methylcholanthrene-pretreated rats.

Authors:  E Hietanem
Journal:  Pharmacology       Date:  1980       Impact factor: 2.547

7.  Blood selenium content and glutathione peroxidase activity in children with cystic fibrosis, coeliac disease, asthma, and epilepsy.

Authors:  K P Ward; J R Arthur; G Russell; P J Aggett
Journal:  Eur J Pediatr       Date:  1984-04       Impact factor: 3.183

8.  Intestinal malignant lymphoma in a child with familial celiac disease.

Authors:  F Arnaud-Battandier; J Schmitz; C Ricour; J Rey
Journal:  J Pediatr Gastroenterol Nutr       Date:  1983-05       Impact factor: 2.839

9.  Prediagnostic serum selenium and risk of cancer.

Authors:  W C Willett; B F Polk; J S Morris; M J Stampfer; S Pressel; B Rosner; J O Taylor; K Schneider; C G Hames
Journal:  Lancet       Date:  1983-07-16       Impact factor: 79.321

10.  Intestinal absorption and metabolism of xenobiotics.

Authors:  R S Chhabra
Journal:  Environ Health Perspect       Date:  1979-12       Impact factor: 9.031

View more
  8 in total

1.  Neonatal pharmacology: extensive interindividual variability despite limited size.

Authors:  Cuneyt Tayman; Maisa Rayyan; Karel Allegaert
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

2.  Postpubertal gluten challenge in coeliac disease.

Authors:  M Mäki; M L Lähdeaho; O Hällström; M Viander; J K Visakorpi
Journal:  Arch Dis Child       Date:  1989-11       Impact factor: 3.791

Review 3.  Formulation Challenges and Strategies to Develop Pediatric Dosage Forms.

Authors:  Wedad A Malkawi; Enas AlRafayah; Mohammad AlHazabreh; Salam AbuLaila; Abeer M Al-Ghananeem
Journal:  Children (Basel)       Date:  2022-04-01

4.  Genetic polymorphisms in biotransformation enzymes in Crohn's disease: association with microsomal epoxide hydrolase.

Authors:  D J de Jong; E M J van der Logt; A van Schaik; H M J Roelofs; W H M Peters; T H J Naber
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

Review 5.  Celiac disease, inflammation and oxidative damage: a nutrigenetic approach.

Authors:  Gianna Ferretti; Tiziana Bacchetti; Simona Masciangelo; Letizia Saturni
Journal:  Nutrients       Date:  2012-03-27       Impact factor: 5.717

Review 6.  Recent advances in the ontogeny of drug disposition.

Authors:  Brian D Chapron; Alenka Chapron; J Steven Leeder
Journal:  Br J Clin Pharmacol       Date:  2021-04-15       Impact factor: 3.716

Review 7.  Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions.

Authors:  Jean-Marie Nicolas; François Bouzom; Chanteux Hugues; Anna-Lena Ungell
Journal:  Biopharm Drug Dispos       Date:  2017-02-06       Impact factor: 1.627

8.  Oxidative stress as a biomarker for monitoring treated celiac disease.

Authors:  Sarah Moretti; Simona Mrakic-Sposta; Leda Roncoroni; Alessandra Vezzoli; Cinzia Dellanoce; Erika Monguzzi; Federica Branchi; Francesca Ferretti; Vincenza Lombardo; Luisa Doneda; Alice Scricciolo; Luca Elli
Journal:  Clin Transl Gastroenterol       Date:  2018-06-08       Impact factor: 4.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.